Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
8.44
+0.20 (2.43%)
Aug 13, 2025, 4:00 PM - Market closed
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey Meckler |
Contact Details
Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | 646 427 2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J204 |
| ISIN Number | US45339J2042 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey A. Meckler J.D. | Chief Executive Officer and Director |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
| Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 29, 2025 | 8-K | Current Report |
| Jul 16, 2025 | 8-K | Current Report |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 23, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 20, 2025 | D | Notice of Exempt Offering of Securities |